Denali Therapeutics Inc. (DNLI)

Denali Therapeutics Revenue

Denali Therapeutics had revenue of $295.39M in the twelve months ending March 31, 2024, with 191.13% growth year-over-year. In the year 2023, Denali Therapeutics had annual revenue of $330.53M with 204.74% growth.

• Revenue (ttm): $295.39M
• Revenue Growth: +191.13%
• P/S Ratio: 10.50
• Revenue / Employee: $663,798
• Employees: 445
• Market Cap: 3.10B USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	330.53M	222.07M	204.74%
Dec 31, 2022	108.46M	59.80M	122.90%
Dec 31, 2021	48.66M	-287.00M	-85.50%
Dec 31, 2020	335.66M	308.98M	1,158.19%
Dec 31, 2019	26.68M	-102.48M	-79.35%
Dec 31, 2018	129.16M	-	-
Dec 31, 2017	0	-	-
Dec 31, 2016	0	-	-
Dec 31, 2015	0	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.